DK1517921T3 - Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf - Google Patents

Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf

Info

Publication number
DK1517921T3
DK1517921T3 DK03738294T DK03738294T DK1517921T3 DK 1517921 T3 DK1517921 T3 DK 1517921T3 DK 03738294 T DK03738294 T DK 03738294T DK 03738294 T DK03738294 T DK 03738294T DK 1517921 T3 DK1517921 T3 DK 1517921T3
Authority
DK
Denmark
Prior art keywords
antigen binding
binding domains
single variable
immunoglobulin single
specific constructs
Prior art date
Application number
DK03738294T
Other languages
Danish (da)
English (en)
Inventor
Greg Winter
Ian Tomlinson
Olga Ignatovich
Lucy Holt
Angelis Elena De
Phillip Jones
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30001956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1517921(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2002/003014 external-priority patent/WO2003002609A2/fr
Priority claimed from GB0230202A external-priority patent/GB0230202D0/en
Application filed by Domantis Ltd filed Critical Domantis Ltd
Application granted granted Critical
Publication of DK1517921T3 publication Critical patent/DK1517921T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Detergent Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK03738294T 2002-06-28 2003-06-30 Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf DK1517921T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2002/003014 WO2003002609A2 (fr) 2001-06-28 2002-06-28 Ligand
GB0230202A GB0230202D0 (en) 2002-12-27 2002-12-27 Ligand

Publications (1)

Publication Number Publication Date
DK1517921T3 true DK1517921T3 (da) 2006-10-09

Family

ID=30001956

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03738294T DK1517921T3 (da) 2002-06-28 2003-06-30 Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf

Country Status (16)

Country Link
US (5) US20060106203A1 (fr)
EP (4) EP2366718A3 (fr)
JP (2) JP2006512895A (fr)
CN (1) CN1678634A (fr)
AT (1) ATE328906T1 (fr)
AU (1) AU2003244817B2 (fr)
CA (1) CA2492092A1 (fr)
CY (1) CY1105191T1 (fr)
DE (1) DE60305919T2 (fr)
DK (1) DK1517921T3 (fr)
ES (1) ES2263984T3 (fr)
GB (1) GB0501752D0 (fr)
HK (1) HK1070081A1 (fr)
PT (1) PT1517921E (fr)
SI (1) SI1517921T1 (fr)
WO (1) WO2004003019A2 (fr)

Families Citing this family (505)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
JP3614866B2 (ja) * 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
IL140701A0 (en) * 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using antibodies to aminophospholipids
PT1135498E (pt) 1998-11-18 2008-04-30 Genentech Inc Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
DE60137421D1 (de) * 2000-06-29 2009-03-05 Abbott Lab Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (fr) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Proteines de liaison specifiques et utilisations associees
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
ATE328906T1 (de) 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1539235A2 (fr) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Anticorps qui se lient specifiquement a reg iv
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
WO2010081856A1 (fr) 2009-01-14 2010-07-22 Ablynx Nv Administration par voie pulmonaire de domaines variables uniques d'immunoglobulines et de constructions associées
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004041865A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique stabilises
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
KR101329843B1 (ko) 2002-11-15 2013-11-14 젠맵 에이/에스 Ｃｄ25에 대한 인간 모노클로날 항체
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
PT2270048E (pt) 2002-12-24 2016-02-10 Rinat Neuroscience Corp Anticorpos anti-ngf e métodos de utilização dos mesmos
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2527871T3 (es) * 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
EP1641826A2 (fr) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Purification et synthese preferentielle de polypeptides de liaison
CA2529819A1 (fr) * 2003-06-30 2004-09-23 Domantis Limited Anticorps a domaine unique pegyles
EP1531162A1 (fr) * 2003-11-14 2005-05-18 Heinz Vollmers Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
CA2555820C (fr) * 2004-02-19 2016-01-19 Genentech, Inc. Anticorps a regions hypervariables reparees
EA012622B1 (ru) 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
ATE548387T1 (de) * 2004-06-29 2012-03-15 Brahms Gmbh Neue monoklonale schilddrüsen-stimulierende oder -blockierende antikörper, korrespondierende peptidesquenzen ihrer variablen regionen, und deren verwendung in diagnostik, präventiver und therapeutischer medizin
EP2322554A1 (fr) * 2004-06-30 2011-05-18 Domantis Limited Composition comprenant un domain-anticorps contre le TNF-alpha pour le traitement de l'arthrite rheumatoïde
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
WO2006019906A1 (fr) * 2004-07-14 2006-02-23 The Regents Of The University Of California Biomarqueur pour detecter de maniere precoce un cancer des ovaires
KR101443473B1 (ko) * 2004-07-22 2014-09-22 에라스무스 유니버시티 메디컬 센터 로테르담 Ｖh 결합 영역의 분리 방법
WO2006033702A2 (fr) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anticorps anti-cd154
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CN101724071A (zh) * 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
EP1799259B1 (fr) * 2004-10-12 2012-12-05 Crucell Holland B.V. Molécules de liaison pour la détection de cancer
WO2006056306A2 (fr) * 2004-11-25 2006-06-01 Unilever N.V. Anticorps a chaine lourde et a domaine
AU2005311101B8 (en) * 2004-12-02 2011-03-03 Domantis Limited Anti-IL-IRI single domain antibodies and therapeutic uses
EP2024396A2 (fr) * 2004-12-02 2009-02-18 Domantis Limited Domaines peptidiques plad ayant une demi-vie augmentee dans le serum due a sa conjugaison a des domaines anticorps
NZ555464A (en) * 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
CA2591059C (fr) 2004-12-28 2018-11-06 Innate Pharma Anticorps monoclonaux contre le nkg2a
WO2006074397A2 (fr) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Molecules a liaison cripto
EP1835929B8 (fr) 2005-01-06 2016-07-27 Novo Nordisk A/S Procédés et traitements combinés anti-kir
AU2006205900B8 (en) 2005-01-14 2012-04-05 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets
WO2006083936A2 (fr) * 2005-01-31 2006-08-10 Genentech, Inc. Anticorps anti-ephb2 et methodes d'utilisation associees
CN105535967B (zh) 2005-02-15 2022-05-03 杜克大学 抗cd19抗体及其在肿瘤学中的应用
EP2292248A3 (fr) 2005-03-03 2011-06-29 CovX Technologies Ireland Limited Composés anti-angiogènes
JP2008533115A (ja) * 2005-03-18 2008-08-21 ドマンティス リミテッド カンジダ抗原に対する抗体
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
EP1868647A4 (fr) * 2005-03-24 2009-04-01 Millennium Pharm Inc Anticorps se liant à ov064 et leurs méthodes d'utilisation
EP2322623A3 (fr) 2005-03-25 2011-10-19 National Research Council of Canada Procédé d'isolation de polypeptides solubles
WO2006106903A1 (fr) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha ISOMERES STRUCTURELS sc(Fv)2
CA2604238C (fr) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas
MX2007013304A (es) * 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
CA2960105A1 (fr) 2005-05-20 2006-11-23 Ablynx Nv Nanobodies (nanocorps) perfectionnes pour traiter des troubles medies par une agregation
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
WO2006129828A2 (fr) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Molecule de capture de substance active
WO2006129843A2 (fr) * 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Molecule de capture de substance cible
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
ZA200802247B (en) * 2005-08-15 2009-08-26 Arana Therapeutics Ltd Chimeric antibodies with new world primate regions
CA2625951A1 (fr) * 2005-09-01 2007-03-08 National Research Council Of Canada Anticorps proteiques anti-apoptotiques
EP1945671A2 (fr) 2005-10-12 2008-07-23 MorphoSys AG Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
EP2465870A1 (fr) * 2005-11-07 2012-06-20 Genentech, Inc. Polypeptides de liaison dotés de séquences hypvervariables VH/VL diversifiées et consensuelles
RS57194B1 (sr) * 2005-11-14 2018-07-31 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
EP1957537A2 (fr) * 2005-12-01 2008-08-20 Domantis Limited Formats d'anticorps a domaine competitif qui lient le recepteur type 1 d'interleukine 1
AU2006321364B2 (en) * 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
KR20080077261A (ko) * 2005-12-06 2008-08-21 도만티스 리미티드 Ｅｇｆｒ 및/또는 ｖｅｇｆ에 대해 결합 특이성이 있는리간드 및 그의 사용 방법
KR20080090414A (ko) * 2005-12-06 2008-10-08 도만티스 리미티드 세포 표면 표적에 대한 결합 특이성이 있는 이중 특이성리간드 및 이의 사용방법
RU2008128134A (ru) 2005-12-15 2010-01-20 Дженентек, Инк. (Us) Способы и композиции для получения направленности на полиубиквитин
ES2291103B1 (es) 2005-12-30 2009-02-01 Universidad Publica De Navarra Metodo y sistema de control del convertidor de una instalacion de generacion electrica conectada a una red electrica ante la presencia de huecos de tension en dicha red.
EP1806365A1 (fr) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
CA2636854A1 (fr) * 2006-01-24 2007-08-02 Domantis Limited Ligands qui lient il-4 et/ou il-13
NZ569988A (en) 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
CA2641310C (fr) * 2006-02-03 2013-08-20 Imclone Systems Incorporated Antagonistes d'igf-ir en tant qu'adjuvants au traitement du cancer de la prostate
EP2540741A1 (fr) 2006-03-06 2013-01-02 Aeres Biomedical Limited Anticorps humanisés anti CD22 et leur utilisation dans le traitement de l'oncologie, la transplantation et les maladies auto-immunes
EP1999147A1 (fr) * 2006-03-27 2008-12-10 Ablynx N.V. Dispositif d'administration medicale pour proteines therapeutiques sur la base d'anticorps a domaine unique
WO2007114325A1 (fr) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'anticorps pour purifier un anticorps bispécifique
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20070274985A1 (en) * 2006-05-26 2007-11-29 Stefan Dubel Antibody
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
MX2008015866A (es) * 2006-06-12 2009-01-14 Centocor Inc Metodo para detectar actividad de interleucina-16 y modulacion de la actividad de interleucina-16 con base en niveles proxi de celulas t normales expresadas y secretadas, reguladas sobre activacion.
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
NO346945B1 (no) 2006-06-30 2023-03-13 Novo Nordisk As Anti-NKG2A-antistoffer og anvendelser derav
KR101429783B1 (ko) * 2006-07-12 2014-08-18 가부시키가이샤 진 테크노 사이언스 항 인간 α９ 인테그린 항체와 그 용도
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
PT2059535E (pt) 2006-08-18 2014-01-29 Novartis Ag Anticorpos específicos do prlr e suas utulizações
WO2008027236A2 (fr) 2006-08-30 2008-03-06 Genentech, Inc. Anticorps multispécifiques
BRPI0714893A2 (pt) 2006-09-05 2013-05-28 Medarex Inc anticorpo monoclonal isolado ou uma porÇço de ligaÇço ao seu antÍgeno, um fragmento de anticorpo, um anticorpo mimÉtico, imunoconjugado, composiÇço molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-bmp2 ou anti-bmp4, mÉtodo para tratar ou prevenir uma doenÇa associada com formaÇço àssea normal e ossificaÇço, hibridoma e metodo para preparar o anticorpo
EP1900752A1 (fr) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Anticorps monoclonaux humains et ses fragments liant spécifiquement le récepteur alpha de l'acide folique pour l'immunothérapie du cancer de l'ovaire
GB0619291D0 (en) * 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
ES2625798T3 (es) 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
AU2007306340A1 (en) * 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and use thereof
CA2665528C (fr) * 2006-10-12 2018-01-23 The University Of Tokyo Diagnostic et traitement du cancer a l'aide d'un anticorps anti-ereg
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
CN103073641B (zh) * 2006-11-10 2015-01-21 株式会社立富泰克 在体内具有抗肿瘤活性的抗人Dlk-1抗体
NZ576751A (en) 2006-11-10 2011-10-28 Covx Technologies Ireland Ltd Anti-angiogenic compounds
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101626782B (zh) 2006-12-01 2013-03-27 梅达雷克斯公司 结合cd22的人抗体及其用途
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AU2007333098A1 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind CD70 and uses thereof
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2103628A4 (fr) * 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d'un tel anticorps
EP2102244A2 (fr) 2006-12-19 2009-09-23 Ablynx N.V. Séquences d'acides aminés dirigées contre une métalloprotéinase de la famille adam et polypeptides les comprenant à des fins de traitement de maladies et troubles liés à adam
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008082651A2 (fr) * 2006-12-29 2008-07-10 Abbott Laboratories Anticorps il-1a/il-1b à double spécificité
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
EP3248617A3 (fr) * 2007-02-16 2018-02-21 Merrimack Pharmaceuticals, Inc. Anticorps dirigés contre l'erbb3 et leurs utilisations
WO2008104803A2 (fr) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Protéines
EP3118221B1 (fr) 2007-02-26 2019-08-21 Oxford BioTherapeutics Ltd Proteines
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
ES2369946T3 (es) * 2007-03-01 2011-12-09 Symphogen A/S Procedimiento para clonación de anticuerpos análogos.
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
CN103214577B (zh) * 2007-03-22 2015-09-02 生物基因Ma公司 特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
JP5779350B2 (ja) 2007-03-27 2015-09-16 シー レーン バイオテクノロジーズ， エルエルシー 抗体代替軽鎖配列を含む構築物およびライブラリー
WO2008122039A2 (fr) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
EP2190875B1 (fr) * 2007-04-23 2019-07-10 Sudhir Paul Anticorps catalytiques contre le VIH gp120
CA2685213C (fr) * 2007-05-04 2017-02-21 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Domaines variables transgeniques d'anticorps de lapin et leurs utilisations
JP5575636B2 (ja) 2007-05-07 2014-08-20 メディミューン，エルエルシー 抗ｉｃｏｓ抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
EP2164992B1 (fr) * 2007-05-30 2016-05-04 Lpath, Inc. Compositions et procédés pour lier de l'acide lysophosphatidique
WO2008153926A2 (fr) 2007-06-05 2008-12-18 Yale University Inhibiteurs de récepteurs tyrosine kinases et leurs méthodes d'utilisation
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
KR20100018040A (ko) * 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
JP5901877B2 (ja) 2007-07-27 2016-04-13 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
EP2535349A1 (fr) 2007-09-26 2012-12-19 UCB Pharma S.A. Fusions d'anticorps à double spécificité
EA201000718A1 (ru) 2007-11-02 2011-06-30 Новартис Аг Молекулы и способы, предназначенные для модуляции родственного рецептору липопротеидов низкой плотности белка 6 (lrp6)
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
BRPI0819063A2 (pt) 2007-11-27 2020-08-18 The University Of British Columbia método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica
EP3239178A1 (fr) 2007-12-14 2017-11-01 Bristol-Myers Squibb Company Molécules de liaison au récepteur humain ox40
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
WO2009088805A2 (fr) 2008-01-03 2009-07-16 The Scripps Research Institute Ciblage d'anticorps par domaine de reconnaissance modulaire
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
WO2009089295A2 (fr) 2008-01-07 2009-07-16 Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Anticorps à domaine anti-vih et procédé de fabrication et d'utilisation de ceux-ci
US9274119B2 (en) * 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
CN102015769B (zh) * 2008-01-17 2014-12-10 Irm责任有限公司 改进的抗-trkb抗体
US8133488B2 (en) 2008-01-18 2012-03-13 Genentech, Inc. Methods and compositions for targeting polyubiquitin
BRPI0908508A2 (pt) 2008-01-24 2016-03-22 Novo Nordisk As anticorpo monoclonal nkg2a anti-humano humanizado
MX2010009722A (es) 2008-03-04 2010-09-30 Pfizer Ltd Procedimiento de tratamiento del dolor cronico.
CA2717015A1 (fr) 2008-03-05 2009-09-11 Ablynx Nv Nouveaux complexes dimeres de fixation a des antigenes, procedes de fabrication et utilisations associes
US8017118B2 (en) * 2008-03-17 2011-09-13 LivTech Inc. — Teikyo University Biotechnology Research Center Anti-hDlk-1 antibody having an antitumor activity in vivo
JP2011515478A (ja) * 2008-03-25 2011-05-19 シェーリング コーポレイション 結腸直腸がんを処置または予防するための方法
AU2009228058A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
PL2247304T3 (pl) 2008-04-02 2017-01-31 Macrogenics, Inc. Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
EP2260058A2 (fr) 2008-04-07 2010-12-15 Ablynx N.V. Séquences d acides aminés dirigées contre les voies notch et leurs utilisations
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2009127691A1 (fr) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant
CA2722137C (fr) 2008-04-28 2019-03-19 Kalobios Pharmaceuticals, Inc. Anticorps du facteur de stimulation de colonies de macrophages et de granulocytes
PT2285408T (pt) 2008-06-05 2019-02-01 Ablynx Nv Sequências de aminoácidos dirigidas contra proteínas de envelope de um vírus e polipéptidos que as compreendem para o tratamento de doenças virais
EP2310855B1 (fr) 2008-06-18 2015-01-28 California Institute of Technology Agents de capture multiligands et compositions, procédés et systèmes associés
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
WO2010009391A1 (fr) 2008-07-18 2010-01-21 Bristol-Myers Squibb Company Compositions monovalentes pour liaison à cd28, et procédés d'utilisation
EP3629022A1 (fr) 2008-07-25 2020-04-01 Richard W. Wagner Procédés de criblage de protéines
EP2318548B1 (fr) 2008-08-15 2013-10-16 Merrimack Pharmaceuticals, Inc. Procédés, systèmes et produits pour prévoir une réponse de cellules tumorales à un agent thérapeutique, et traitement d'un patient selon la réponse prévue
WO2010027767A1 (fr) * 2008-08-27 2010-03-11 Schering Corporation Anticorps anti-il-23r modifiés
AU2009288167B2 (en) 2008-09-03 2015-10-22 Genentech, Inc. Multispecific antibodies
EP2331579B1 (fr) * 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Anticorps monoclonaux
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
EP2352765B1 (fr) * 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Anticorps monocaténaire bispécifique à domaine unique, spécifique d'espèces croisées
AU2009305113B2 (en) * 2008-10-13 2015-07-16 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
MX2011004558A (es) 2008-10-29 2011-06-01 Wyeth Llc Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
CA2743469C (fr) 2008-11-12 2019-01-15 Medimmune, Llc Formulation d'anticorps
UA105198C2 (ru) 2008-12-12 2014-04-25 Берингер Ингельхайм Интернациональ Гмбх Антитело против инсулиноподобных факторов роста
WO2010084408A2 (fr) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Protéine pta089
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
AU2010208125B2 (en) * 2009-01-29 2015-02-12 Medimmune, Llc Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
AU2010210312A1 (en) * 2009-02-09 2011-08-04 Patrys Limited SAM-6 variants, target and methods of use
JP2012517818A (ja) 2009-02-19 2012-08-09 グラクソ グループ リミテッド 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト
BRPI1008705B1 (pt) 2009-02-19 2021-05-25 Glaxo Group Limited Domínio variável único da imunoglobulina anti-soro albumina, ligante multiespecífico compreendendo o dito domínio, proteína de fusão fundida ao dito domínio, composição, ácido nucleico e vetor compreendendo o dito ácido nucleico
EP3656788A3 (fr) 2009-02-19 2020-07-29 Glaxo Group Limited Variants de liaison anti-albumine sérique améliorés
CA2753287A1 (fr) 2009-02-24 2010-09-02 Glaxo Group Limited Constructions de liaison d'antigene
WO2010100135A1 (fr) 2009-03-05 2010-09-10 Ablynx N.V. Nouveaux complexes dimères de liaison antigénique, méthodes d'obtention/non obtention et leurs utilisations
EA028336B1 (ru) 2009-03-05 2017-11-30 МЕДАРЕКС Л.Л.Си. Полностью человеческие антитела, специфические в отношении cadm1
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
TWI461211B (zh) 2009-03-20 2014-11-21 Genentech Inc 抗－ｈｅｒ抗體
EP2411050A4 (fr) 2009-03-25 2013-07-17 Vet Therapeutics Inc Régions de domaine constant d'anticorps et leurs utilisations
BRPI1014089A2 (pt) * 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
JP5647222B2 (ja) 2009-04-10 2014-12-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患及び障害の治療のためのｉｌ−６ｒに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド
CA2759538C (fr) 2009-04-20 2018-07-24 Oxford Biotherapeutics Ltd Anticorps specifiques a la cadherine-17
US20120058116A1 (en) 2009-04-24 2012-03-08 Andrew Beaton Fgfr1c antibody combinations
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
WO2010137654A1 (fr) 2009-05-29 2010-12-02 株式会社未来創薬研究所 Composition pharmaceutique contenant un antagoniste d'un ligand de la famille de l'egf en tant que composant
DK2438087T3 (en) * 2009-06-05 2017-08-28 Ablynx Nv TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2448966B1 (fr) * 2009-07-03 2018-11-14 Avipep Pty Ltd Immunoconjugués et leurs procédés de production
EA201270174A1 (ru) 2009-07-16 2012-07-30 Глэксо Груп Лимитед Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина
CA2768460A1 (fr) 2009-07-16 2011-01-20 Glaxo Group Limited Antagonistes, utilisations, et procedes pour inhiber partiellement le tnfr1
KR20120063475A (ko) 2009-07-29 2012-06-15 글락소 그룹 리미티드 항-ｔｇｆ-베타 수용체 타입 ⅱ 단일 도메인 항체
EP3165236B1 (fr) 2009-08-28 2022-03-16 Teva Pharmaceuticals International GmbH Procédés de traitement de la douleur viscérale par administration d'anticorps d'antagonistes dirigés contre un peptide associé au gène de la calcitonine
MX2012002605A (es) 2009-08-29 2012-04-02 Abbott Lab Proteinas terapeutico de union a dll4.
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
IN2012DN02401A (fr) 2009-09-24 2015-08-21 Ucb Pharma Sa
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
RU2583298C2 (ru) 2009-10-07 2016-05-10 Макродженикс, Инк. ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2485761B1 (fr) 2009-10-09 2019-02-27 Armagen, Inc. Procédés et compositions destinés à augmenter l'activité iduronate 2-sulfatase dans le snc
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
TW201125877A (en) 2009-10-27 2011-08-01 Glaxo Group Ltd Stable anti-TNFR1 polypeptides, antibody variable domains & and antagonists
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
LT2954779T (lt) 2009-12-10 2019-05-27 Regeneron Pharmaceuticals, Inc. Pelės, gaminančios sunkiosios grandinės antikūnus
WO2011073180A1 (fr) 2009-12-14 2011-06-23 Ablynx N.V. Anticorps à domaine variable unique dirigés contre ox4ql, produits de recombinaison et utilisation thérapeutique
WO2011075786A1 (fr) * 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugués et leurs méthodes de production
WO2011083140A1 (fr) 2010-01-08 2011-07-14 Ablynx Nv Domaines variables simples d'immunoglobuline dirigés contre le cxcr4 doués d'une meilleure activité thérapeutique et produits de recombinaison les comprenant
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
JP2013518853A (ja) 2010-02-05 2013-05-23 アブリンクス エン．ヴェー． 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2533810B1 (fr) 2010-02-10 2016-10-12 ImmunoGen, Inc. Anticorps anti-cd20 et utilisations de ceux-ci
WO2011098449A1 (fr) 2010-02-10 2011-08-18 Novartis Ag Procédés et composés pour la croissance de muscle
WO2011098518A2 (fr) 2010-02-11 2011-08-18 Ablynx Nv Administration de domaines variables d'immunoglobuline et de produits de construction de ceux-ci
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
JP2013520999A (ja) 2010-03-04 2013-06-10 ベット・セラピューティクス・インコーポレイテッド Ｃｄ５２に対するモノクローナル抗体
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
SG183532A1 (en) 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
BR112012026174A2 (pt) 2010-04-15 2019-09-24 Genentech Inc anticorpo isolado, ácido nucleico isolado, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, doença ou disfunção, uso do anticorpo, método de tratamento, de determinação e de separação
EP2560992A2 (fr) 2010-04-21 2013-02-27 Glaxo Group Limited Domaines de liaison
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
BR112012029280A2 (pt) 2010-05-20 2016-11-29 Glaxo Group Ltd variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão
WO2011144749A1 (fr) 2010-05-20 2011-11-24 Ablynx Nv Matériaux biologiques associés à her3
EP3327035A1 (fr) 2010-06-22 2018-05-30 Precision Biologics Inc. Antigènes et anticorps spécifiques des cancers du côlon et du pancréas
WO2011161263A1 (fr) 2010-06-25 2011-12-29 Ablynx Nv Compositions pharmaceutiques destinées à une administration par voie cutanée
WO2012009705A1 (fr) 2010-07-15 2012-01-19 Zyngenia, Inc. Complexes liant ang-2 et leurs utilisations
EP2593476A2 (fr) 2010-07-16 2013-05-22 Ablynx N.V. Molécules de liaison à un antigène à domaine unique modifiées et leurs utilisations
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
DK2601298T3 (en) 2010-08-02 2017-02-27 Regeneron Pharma Mice generating binding proteins comprising VL domains
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2013538566A (ja) 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
CA2808154A1 (fr) 2010-08-13 2012-02-16 Medimmmune Limited Polypeptides monomeres comprenant des regions du variant fc et procedes d'utilisation de ceux-ci
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
WO2012022734A2 (fr) 2010-08-16 2012-02-23 Medimmune Limited Anticorps anti-icam-1 et procédés d'utilisation
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
PT2606070T (pt) 2010-08-20 2017-03-31 Novartis Ag Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
JP2013537421A (ja) 2010-08-20 2013-10-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
CA2807278A1 (fr) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Anticorps bispecifiques comprenant un fragment fv stabilise par bisulfure
RU2710717C2 (ru) 2010-09-09 2020-01-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1ВВ
EP3578568A3 (fr) 2010-11-08 2020-01-08 Ablynx N.V. Polypeptides se liant aux récepteurs de cxcr2
JP6173216B2 (ja) 2010-11-26 2017-08-02 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール
RU2663123C2 (ru) * 2010-11-30 2018-08-01 Чугаи Сейяку Кабусики Кайся Индуцирующий цитотоксичность терапевтический агент
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
WO2012075340A2 (fr) 2010-12-01 2012-06-07 Alderbio Holdings Llc Compositions anti-ngf et leur utilisation
JP2014501515A (ja) 2010-12-01 2014-01-23 グラクソ グループ リミテッド 改良された抗血清アルブミン結合単一可変ドメイン
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2012085111A1 (fr) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
EP3613773A1 (fr) * 2010-12-27 2020-02-26 Apo-T B.V. Polypeptide de réticulation induisant l'apoptose
WO2012093125A1 (fr) 2011-01-06 2012-07-12 Glaxo Group Limited Ligands se liant au récepteur ii du tgf-bêta
JP2014505698A (ja) 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
CA2827170A1 (fr) 2011-02-11 2012-08-16 David M. Hilbert Complexes plurispecifiques monovalents et multivalents et leurs utilisations
CA2824824A1 (fr) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Proteines monovalentes de liaison a l'antigene
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
SG10201602371VA (en) * 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
WO2012131053A1 (fr) 2011-03-30 2012-10-04 Ablynx Nv Méthodes de traitement de troubles immunitaires par des anticorps à domaine unique dirigés contre tnf-alpha
EP2691156A1 (fr) 2011-03-30 2014-02-05 Boehringer Ingelheim International GmbH Antidotes aux anticoagulants
US9701740B2 (en) 2011-04-01 2017-07-11 Yale University Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
LT3495392T (lt) 2011-05-20 2021-09-27 H. Lundbeck A/S Anti-cgrp kompozicijos ir jų panaudojimas
KR101965461B1 (ko) 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
NZ732875A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
WO2012162561A2 (fr) 2011-05-24 2012-11-29 Zyngenia, Inc. Complexes plurispécifiques multivalents et monovalents, et leurs utilisations
AU2012264809B2 (en) 2011-05-27 2017-05-04 Ablynx Nv Inhibition of bone resorption with RANKL binding peptides
WO2012166906A1 (fr) 2011-05-31 2012-12-06 Massachusetts Institute Of Technology Synthèse dirigée par des cellules de nanomotifs et nanomatériaux multifonctionnels
AU2012268939B2 (en) 2011-06-17 2017-05-04 Novo Nordisk A/S Selective elimination of erosive cells
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
PL2726094T3 (pl) 2011-06-28 2017-06-30 Oxford Biotherapeutics Ltd Cel terapeutyczny i diagnostyczny
PT2726508T (pt) 2011-06-28 2017-09-26 Oxford Biotherapeutics Ltd Anticorpos para adp-ribosil ciclase 2
KR102077721B1 (ko) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
BR112013032871B1 (pt) 2011-07-13 2022-09-27 Ucb Pharma S.A. Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2842860A1 (fr) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Proteines se liant a sur dirigees contre erbb3
EP2739651B1 (fr) 2011-08-05 2019-02-20 Genentech, Inc. Anticorps anti-polyubiquitine et méthodes d'utilisation
EA027160B1 (ru) 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
JO3625B1 (ar) 2011-09-22 2020-08-27 Amgen Inc بروتينات رابطة للأنتيجين cd27l
SG10201504605RA (en) * 2011-09-23 2015-07-30 Technophage Investigação E Desenvolvimento Em Biotecnologia Sa Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof
EP2747782B1 (fr) 2011-09-23 2018-01-17 Ablynx NV Inhibition prolongée d'une signalisation à médiation par l'interleukine-6
EP2760892A1 (fr) 2011-09-29 2014-08-06 Apo-T B.V. Molécules de liaison multispécifiques ciblant des cellules aberrantes
CA2850436C (fr) 2011-09-30 2021-06-22 Adi Mashiach Appareil et procede de commande d'un apport d'energie en fonction d'un degre de couplage
US9127056B2 (en) 2011-10-17 2015-09-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
US20130122005A1 (en) 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
CA2853230C (fr) 2011-10-31 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Molecule de liaison a un antigene a conjugaison regulee entre une chaine lourde et une chaine legere
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
RU2014122602A (ru) 2011-11-04 2015-12-10 Новартис Аг Конструкции на основе белка, родственного липопротеинам низкой плотности, 6(lrp6), и удлинителя полупериода существования
SG11201401649VA (en) 2011-11-11 2014-07-30 Ucb Pharma Sa Albumin binding antibodies and binding fragments thereof
WO2013081706A1 (fr) 2011-12-02 2013-06-06 Armagen Technologies, Inc. Méthodes et compositions pour augmenter l'activité arylsulfatase a dans le système nerveux central
KR102083957B1 (ko) 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
KR20140103135A (ko) 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
PT2793567T (pt) 2011-12-20 2019-05-27 Regeneron Pharma Murganhos de cadeia leve humanizada
ES2710916T3 (es) 2011-12-22 2019-04-29 I2 Pharmaceuticals Inc Proteínas de unión sustitutas
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
US20130183307A1 (en) 2012-01-13 2013-07-18 Johan Renes Aberrant cell-restricted immunoglobulins provided with a toxic moiety
EP2809682B1 (fr) * 2012-02-03 2020-04-08 F.Hoffmann-La Roche Ag Molécules d'anticorps bispécifiques avec des lymphocytes t transfectés par un antigène et leur utilisation en médecine
WO2013119966A2 (fr) * 2012-02-10 2013-08-15 Genentech, Inc. Anticorps et autres hétéromultimères monocaténaires
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
KR101505157B1 (ko) * 2012-05-08 2015-03-24 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
BR112014028366A2 (pt) * 2012-05-21 2017-06-27 Genentech Inc anticorpos anti-ly6e e imunoconjugados e métodos de uso
KR20150013188A (ko) * 2012-05-24 2015-02-04 에프. 호프만-라 로슈 아게 다중특이적 항체
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
EP2867253B1 (fr) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Méthode de sélection et de production d'entités de ciblage personnalisées fortement sélectives et multi-spécifiques renfermant au moins deux entités de liaison différentes et leurs utilisations
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014022540A1 (fr) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Protéines multivalentes de liaison à un antigène
WO2014029752A1 (fr) 2012-08-22 2014-02-27 Glaxo Group Limited Anticorps anti-lrp6
PL2905335T3 (pl) 2012-10-03 2018-06-29 Chiome Bioscience Inc. Przeciwciało anty-hdlk-1 wykazujące aktywność przeciwnowotworową in vivo
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014085365A2 (fr) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions et méthodes de traitement de troubles et maladies métaboliques
EP2925782B1 (fr) 2012-12-03 2020-01-22 NovImmune SA Anticorps anti-cd47 et leurs procédés d'utilisation
CN104981482A (zh) * 2012-12-05 2015-10-14 迪塔莱斯有限公司 双靶向作用
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
WO2014111550A1 (fr) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Protéines de liaison modifiées anti-albumine sérique
EP2948478B1 (fr) 2013-01-25 2019-04-03 Amgen Inc. Anticorps ciblant cdh19 pour un mélanome
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2014120916A1 (fr) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Anticorps à domaines pegylés monovalents pour la liaison à cd28 et leurs méthodes d'utilisation
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
AU2014223824B2 (en) 2013-02-28 2020-02-27 Albert Einstein College Of Medicine, Inc. Tuberculosis biomarkers and uses thereof
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2014159239A2 (fr) 2013-03-14 2014-10-02 Novartis Ag Anticorps dirigés contre notch 3
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
WO2014144600A2 (fr) 2013-03-15 2014-09-18 Viktor Roschke Complexes multispécifiques multivalents et monovalents et leurs utilisations
RU2714733C2 (ru) * 2013-03-15 2020-02-19 Мемориал Слоан-Кеттеринг Кэнсер Сентер Технологии мультимеризации
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
EP2970484B2 (fr) * 2013-03-15 2022-09-21 Amgen Inc. Anticorps hétérodimères bispécifiques
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
BR112015023862A2 (pt) 2013-03-18 2017-10-24 Biocerox Prod Bv anticorpo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, método de realçar uma resposta imune, método de tratar câncer, composição farmacêutica, e, anticorpo agonístico isolado
NZ753995A (en) 2013-05-30 2022-07-01 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
WO2014198748A1 (fr) * 2013-06-11 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps à domaine unique anti-her2, polypeptides comportant de tels anticorps et leur utilisation pour le traitement du cancer
CA2918795A1 (fr) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Anticorps multispecifiques, anticorps activables multispecifiques et leurs methodes d'utilisation
SG11201600171SA (en) 2013-08-02 2016-02-26 Pfizer Anti-cxcr4 antibodies and antibody-drug conjugates
EP3632930A1 (fr) * 2013-08-30 2020-04-08 Aprilbio Co., Ltd Construction de fusion de fraction d'effecteur fab d'albumine antisérum
WO2015050959A1 (fr) 2013-10-01 2015-04-09 Yale University Anticorps anti-kits et leurs méthodes d'utilisation
AU2014329609B2 (en) 2013-10-02 2019-09-12 Humabs Biomed Sa Neutralizing anti-influenza A antibodies and uses thereof
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
KR102178323B1 (ko) * 2013-11-29 2020-11-13 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
WO2015095539A1 (fr) * 2013-12-20 2015-06-25 Genentech, Inc. Anticorps à double spécificité
WO2015100459A2 (fr) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
SG11201606842RA (en) 2014-02-20 2016-09-29 Allergan Inc Complement component c5 antibodies
EP3110845A1 (fr) 2014-02-27 2017-01-04 Allergan, Inc. Anticorps anti-bb du facteur de complement
US10881085B2 (en) 2014-03-21 2021-01-05 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
SG10201808083VA (en) 2014-03-21 2018-10-30 Regeneron Pharma Vl antigen binding proteins exhibiting distinct binding characteristics
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
KR102352573B1 (ko) * 2014-04-04 2022-01-18 바이오노믹스 인코포레이티드 Ｌｇｒ５에 결합하는 인간화된 항체들
HUE054588T2 (hu) * 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
NZ724710A (en) 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
BR112016026299A2 (pt) 2014-05-13 2018-02-20 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
HUE050007T2 (hu) 2014-05-16 2020-11-30 Ablynx Nv Immunglobulin variábilis domének
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US10238742B2 (en) * 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
CN107108738A (zh) 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
UY36245A (es) * 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
CA2956471A1 (fr) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Constructions optimisees d'anticorps monocatenaires, bispecifiques, specifiques d'especes croisees
KR102259232B1 (ko) * 2014-08-25 2021-05-31 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3209681A4 (fr) 2014-10-23 2018-10-31 NGM Biopharmaceuticals, Inc. Compositions pharmaceutiques comprenant des variants de peptide et leurs procédés d'utilisation
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
JP6787888B2 (ja) 2014-11-10 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｉｌ−１ベータ抗体及び使用方法
SG11201703428SA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Bispecific antibodies and methods of use in ophthalmology
KR20170082594A (ko) * 2014-11-10 2017-07-14 에프. 호프만-라 로슈 아게 항-ang2 항체 및 사용 방법
WO2016087416A1 (fr) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Anticorps multispécifiques
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
JP6862343B2 (ja) * 2014-12-19 2021-04-21 アブリンクス エン．ヴェー． システイン結合ナノボディダイマー
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
WO2016124781A1 (fr) * 2015-02-05 2016-08-11 Ablynx N.V. Dimères nanobody liés par l'intermédiaire de cystéines d'ingénierie au niveau du c-terminal
EP3271403A1 (fr) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Animaux non humains qui sélectionnent des régions variables de chaînes légères qui se lient à l'antigène
SI3280729T1 (sl) 2015-04-08 2022-09-30 Novartis Ag Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
KR101997241B1 (ko) * 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
EP3378488A4 (fr) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Procédé pour renforcer la réponse immunitaire humorale
WO2017086367A1 (fr) 2015-11-18 2017-05-26 中外製薬株式会社 Polythérapie utilisant une molécule de liaison à l'antigène à rôle de redirection des cellules t, ciblant des cellules immunosupressives
KR20180091918A (ko) 2015-12-28 2018-08-16 추가이 세이야쿠 가부시키가이샤 Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
CA3016424A1 (fr) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Medicament therapeutique induisant des lesions cellulaires a utiliser dans le traitement du cancer
JP2019509322A (ja) 2016-03-22 2019-04-04 バイオノミクス リミテッド 抗ｌｇｒ５モノクローナル抗体の投与
US20190119387A1 (en) 2016-04-05 2019-04-25 Glaxosmithkline Intellectual Property Development Limited Inhibition of tgfbeta in immunotherapy
LT3458478T (lt) 2016-05-18 2021-02-10 Boehringer Ingelheim International Gmbh Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10544221B2 (en) 2016-05-20 2020-01-28 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
CN109562146A (zh) * 2016-06-03 2019-04-02 詹森生物科技公司 血清白蛋白结合纤连蛋白iii型结构域
JP2019518040A (ja) 2016-06-15 2019-06-27 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 腫瘍に対して標的化されるナノキャリアの抗体媒介性自触反応的送達
WO2018007442A1 (fr) 2016-07-06 2018-01-11 Ablynx N.V. Traitement de maladies associées à l'il-6r
US11186634B2 (en) 2016-07-29 2021-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies targeting tumor associated macrophages and uses thereof
WO2018029182A1 (fr) 2016-08-08 2018-02-15 Ablynx N.V. Anticorps à domaine variable unique d'il-6r pour le traitement de maladies liées à l'il-6r
BR112019005823A2 (pt) 2016-09-23 2019-06-25 Teva Pharmaceuticals Int Gmbh tratamento para enxaqueca refratária
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
EP3541846A1 (fr) 2016-11-16 2019-09-25 Ablynx NV Polypeptides de recrutement de lymphocytes t capables de se lier à cd123 et tcr alpha/bêta
WO2018098354A1 (fr) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Protéine de liaison à l'antigène membranaire spécifique de la prostate
BR112019010602A2 (pt) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc proteínas trispecíficas para psma e métodos de uso
AU2017373746A1 (en) 2016-12-07 2019-05-30 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3360898A1 (fr) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
SG11201906341XA (en) 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders
MX2019008496A (es) 2017-01-17 2019-09-18 Ablynx Nv Aglutinantes de albumina serica mejorados.
EP3576790A4 (fr) 2017-02-01 2020-12-23 Yale University Traitement de la résistance aux diurétiques
WO2018160754A2 (fr) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Protéine monovalente inductible de fixation d' antigène
WO2018158398A1 (fr) 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps présentant une spécificité pour la nectine-4 et leurs utilisations
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
MX2019014331A (es) * 2017-05-31 2020-01-27 Boehringer Ingelheim Int Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales.
IL253015B2 (en) 2017-06-18 2023-07-01 Israel Aerospace Ind Ltd System and method for refueling aerial vehicles
IL253407B (en) 2017-07-10 2020-08-31 Israel Aerospace Ind Ltd refueling station
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
CN111511762A (zh) 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
EP3694873A1 (fr) 2017-10-10 2020-08-19 Numab Therapeutics AG Anticorps multispécifiques
EP3470426A1 (fr) 2017-10-10 2019-04-17 Numab Therapeutics AG Anticorps multi-spécifique
PE20201183A1 (es) 2017-10-13 2020-11-03 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso
US10927180B2 (en) 2017-10-13 2021-02-23 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
WO2019075405A1 (fr) 2017-10-14 2019-04-18 Cytomx Therapeutics, Inc. Anticorps, anticorps activables, anticorps bispécifiques, et anticorps activables bispécifiques et leurs procédés d'utilisation
CA3087699A1 (fr) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methodes de traitement d'une inflammation mediee par il-6 sans immunosuppression
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
WO2019148444A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps anti-ctla4 et leurs procédés de fabrication et d'utilisation
EP3569618A1 (fr) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonisation d'anticorps cd73
EP3818083A2 (fr) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
WO2020014306A1 (fr) 2018-07-10 2020-01-16 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
US20220047701A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
IL297931A (en) 2018-09-25 2023-01-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
WO2020084056A1 (fr) 2018-10-25 2020-04-30 Swiss Pharma International Ag Anticorps anti-cd89 humains et leurs utilisations
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
WO2020115283A1 (fr) * 2018-12-07 2020-06-11 Baxalta GmbH Anticorps bispécifiques fixant le facteur ixa et le facteur x
WO2020114615A1 (fr) * 2018-12-07 2020-06-11 Baxalta GmbH Anticorps bispécifiques se liant au facteur ixa et au facteur x
WO2020146527A1 (fr) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
CN113631573B (zh) 2019-03-25 2024-06-04 国家医疗保健研究所 抗Tau抗体及其在制备用于治疗疾病的药物中的用途
WO2020198731A2 (fr) 2019-03-28 2020-10-01 Danisco Us Inc Anticorps modifiés
CN114450304B (zh) 2019-09-27 2023-12-12 国家医疗保健研究所 抗苗勒管抑制物质抗体及其用途
WO2021058729A1 (fr) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps dirigés contre le récepteur de type i d'une substance inhibitrice anti-mullérienne et leurs utilisations
EP3816185A1 (fr) 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
EP4072682A1 (fr) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Anticorps présentant une spécificité pour her4 et leurs utilisations
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
EP4081541A1 (fr) 2019-12-24 2022-11-02 Jjp Biologics Sp. Z O.O. Anticorps anti-hvem (tnfrsf14) anti-humains et leurs utilisations
CN113248611A (zh) 2020-02-13 2021-08-13 湖南华康恒健生物技术有限公司 抗bcma抗体、其药物组合物及应用
JP2023527609A (ja) 2020-02-21 2023-06-30 ハープーン セラピューティクス，インク． Ｆｌｔ３結合タンパク質および使用方法
WO2021205183A1 (fr) 2020-04-09 2021-10-14 Autolus Limited Polypeptide
CA3172618A1 (fr) 2020-04-21 2021-10-28 Jjp Biologics Sp. Z O.O. Anticorps anti-cd89 humains humanises et leurs utilisations
KR20230008751A (ko) 2020-05-12 2023-01-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
CR20220586A (es) 2020-05-19 2023-01-09 Boehringer Ingelheim Int Moléculas de fijación para el tratamiento de cáncer
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
EP3915580A1 (fr) 2020-05-29 2021-12-01 Numab Therapeutics AG Anticorps multi-spécifique
EP4206224A1 (fr) 2020-08-26 2023-07-05 National University Corporation Kumamoto University Anticorps humain ou fragment de liaison à l'antigène de celui-ci dirigé contre une protéine de spicule de coronavirus
CN114106173A (zh) 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
EP4232474A1 (fr) 2020-10-21 2023-08-30 Boehringer Ingelheim International GmbH Molécules de liaison anti-vegf et anti-trkb bispécifiques pour le traitement de maladies oculaires
EP3988568A1 (fr) 2020-10-21 2022-04-27 Numab Therapeutics AG Traitement combiné
WO2022098743A1 (fr) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imagerie et procédés thérapeutiques ciblant le récepteur 1 de folate (folr1)
WO2022098745A1 (fr) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, systèmes d'administration et méthodes utiles dans la thérapie antitumorale
MX2023006650A (es) 2020-12-07 2023-06-21 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos.
EP4288451A1 (fr) 2021-02-02 2023-12-13 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour ror1 et cd3
AU2022224636A1 (en) 2021-02-19 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
EP4355778A1 (fr) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Nouvelles molécules de liaison tri-spécifiques
EP4183800A1 (fr) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Nouveaux anticorps neutralisants du sars-cov-2
WO2023175171A1 (fr) 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anticorps de polyomavirus bk et leurs utilisations
WO2023196932A2 (fr) * 2022-04-06 2023-10-12 The Regents Of The University Of California Isolement de car de lymphocytes t actifs vis-à-vis de lymphocytes t humains transduits en masse
US20240052065A1 (en) 2022-07-15 2024-02-15 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2024038095A1 (fr) 2022-08-16 2024-02-22 Iome Bio Nouveaux anticorps anti-rgmb
WO2024052503A1 (fr) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Anticorps présentant une spécificité pour ltbp2 et leurs utilisations
WO2024056668A1 (fr) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale Nouveaux anticorps anti-itgb8 et leurs utilisations
WO2024083843A1 (fr) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
WO1989006692A1 (fr) * 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
ES2052027T5 (es) * 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
CA2064915C (fr) * 1989-08-07 2001-05-29 Deborah A. Rathjen Ligands de fixation du facteur de necrose tumorale
US5644034A (en) * 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US6451983B2 (en) * 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
AU8869291A (en) 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
US5582996A (en) * 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
SK281142B6 (sk) * 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
OA10149A (en) * 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1993000917A1 (fr) * 1991-07-05 1993-01-21 Seragen, Inc. Molecules ciblees sur un recepteur du facteur de croissance epidermique, et utilisees dans le traitement de l'arthrite inflammatoire
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ATE275198T1 (de) * 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6005079A (en) * 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0656946T4 (da) * 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
US5837242A (en) * 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
EP0721346B1 (fr) * 1993-09-02 1998-06-10 Trustees of Dartmouth College Procedes permettant d'induire la tolerance des cellules t a specificite antigenique
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
ATE208633T1 (de) * 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
US5712381A (en) * 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US5664034A (en) * 1996-05-21 1997-09-02 Lucent Technologies Inc. Lightwave communication monitoring switch
US20040248201A1 (en) * 1996-06-27 2004-12-09 Serge Muyldermans Recognition molecules interacting specifically with the active site or cleft of a target molecule
NZ333602A (en) * 1996-07-08 2000-06-23 Biogen Inc Treatment of smooth muscle cell dependent disease using antibodies capable of inhibiting the CD40 - CD40 ligand interaction
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
DE69726003T2 (de) * 1996-07-16 2004-08-26 Andreas Plückthun Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US20030165467A1 (en) * 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
AUPO561697A0 (en) * 1997-03-13 1997-04-10 Crc For Cardiac Technology Haemocompatible surfaces
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
JP2002507967A (ja) * 1997-06-20 2002-03-12 パンゲネチックス・ベー・ファウ 疾病治療のための抗ｃｄ４０ｌイムノトキシン
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
WO1999023221A2 (fr) 1997-10-27 1999-05-14 Unilever Plc Proteines multivalentes de fixation de l'antigene
US6777534B1 (en) * 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
US20020192211A1 (en) * 1998-03-17 2002-12-19 Hudziak Robert M. Method of treating tumor cells by inhibiting growth factor receptor function
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20030175271A1 (en) * 1998-05-20 2003-09-18 Kyowa Hakko Kogyo Co., Ltd. VEGF activity inhibitor
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
EP1002861A1 (fr) * 1998-10-26 2000-05-24 Unilever Plc Protéines se liant aux antigènes comprenant un liant conférant une flexibilité conformationnelle limitée
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2355976C (fr) * 1998-12-22 2012-07-17 Genentech, Inc. Antagonistes du facteur de croissance endotheliale et leurs utilisations
SE9901379D0 (sv) * 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
AU4770300A (en) 1999-05-14 2000-12-05 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
EE200100603A (et) * 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
CA2373822A1 (fr) * 1999-05-20 2000-11-30 Scios Inc. Variants du facteur de croissance endotheliale
US6419758B1 (en) * 1999-09-10 2002-07-16 General Electric Company Cathode wire filament for x-ray tube applications
AU784285B2 (en) * 1999-12-24 2006-03-02 Genentech Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
DE60131146T2 (de) * 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity
EP1268544A2 (fr) * 2000-03-31 2003-01-02 Institut Pasteur Peptides inhibant l'angiogenese induite par le vegf (facteur de croissance endotheliale), polynucleotides codant pour ces peptides et leurs procedes d'utilisation
NZ521540A (en) * 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
AU2001264920A1 (en) * 2000-05-22 2001-12-03 Ho, Alice, Suk-Yue Therapeutic uses of il-1 receptor antagonist
JP2004511430A (ja) * 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド 二重特異性免疫グロブリン様抗原結合蛋白および製造方法
DE10038624C2 (de) * 2000-08-03 2002-11-21 Broekelmann Aluminium F W Wärmeübertragungsrohr mit gedrallten Innenrippen
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
AU2002211658A1 (en) * 2000-10-13 2002-04-22 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
EP2141243A3 (fr) * 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Supports de protéine pour mimer des anticorps et d'autres protéines de liaison
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1455820A2 (fr) * 2001-03-09 2004-09-15 William Herman Ligands cibles
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
PL363322A1 (en) * 2001-05-08 2004-11-15 Merck Patent Gmbh Combination therapy using anti-egfr antibodies and anti-hormonal agents
CA2450285C (fr) * 2001-06-13 2016-08-02 Genmab A/S Anticorps monoclonaux humains diriges contre le recepteur de facteur de croissance epidermique (egfr)
EP1399484B1 (fr) * 2001-06-28 2010-08-11 Domantis Limited Ligand a double specificite et son utilisation
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
JP2005508887A (ja) * 2001-08-03 2005-04-07 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション Ｅｇｆ受容体の結晶構造に基づいたスクリーニング方法
AU2002319544B2 (en) * 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
KR20050036875A (ko) * 2001-10-15 2005-04-20 이뮤노메딕스, 인코오포레이티드 직접 표적형의 결합 단백질
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
EP1487879B1 (fr) * 2002-03-01 2012-12-26 Immunomedics, Inc. Mutations ponctuelles dans un anticorps bispecifique, permettant d'augmenter le taux de clairance
ATE328906T1 (de) 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
MXPA05002514A (es) * 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
TW200501960A (en) * 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
WO2004041865A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique stabilises
AU2003286003B2 (en) * 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
GB0230201D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Retargeting
JP3983183B2 (ja) * 2003-02-18 2007-09-26 トヨタ車体株式会社 搬送設備
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
KR20180132969A (ko) * 2003-05-30 2018-12-12 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
WO2004110490A2 (fr) * 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Methode de regression tumorale avec des inhibiteurs vegf
AU2004259398A1 (en) * 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050196340A1 (en) * 2003-08-06 2005-09-08 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
JP4818917B2 (ja) * 2003-08-08 2011-11-16 イミューノメディクス、インコーポレイテッド 腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体
CA2550551C (fr) * 2004-01-16 2013-10-29 Regeneron Pharmaceuticals, Inc. Polypeptides hybrides capables d'activer des recepteurs
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof

Also Published As

Publication number Publication date
EP2366718A3 (fr) 2012-05-02
US20070093651A1 (en) 2007-04-26
EP1517921A2 (fr) 2005-03-30
CA2492092A1 (fr) 2004-01-08
EP1600459A3 (fr) 2005-12-07
US20060063921A1 (en) 2006-03-23
EP2366718A2 (fr) 2011-09-21
JP2011125342A (ja) 2011-06-30
PT1517921E (pt) 2006-09-29
DE60305919D1 (de) 2006-07-20
US20150087813A1 (en) 2015-03-26
EP2135879A3 (fr) 2010-06-23
GB0501752D0 (en) 2005-03-02
JP2006512895A (ja) 2006-04-20
EP1517921B1 (fr) 2006-06-07
US20060106203A1 (en) 2006-05-18
WO2004003019A3 (fr) 2004-09-10
AU2003244817A1 (en) 2004-01-19
AU2003244817A2 (en) 2004-01-19
DE60305919T2 (de) 2007-01-18
AU2003244817B2 (en) 2010-08-26
HK1070081A1 (en) 2005-06-10
US20100234570A1 (en) 2010-09-16
SI1517921T1 (sl) 2006-10-31
CN1678634A (zh) 2005-10-05
EP2135879A2 (fr) 2009-12-23
WO2004003019A2 (fr) 2004-01-08
EP1600459A2 (fr) 2005-11-30
ES2263984T3 (es) 2006-12-16
CY1105191T1 (el) 2010-03-03
ATE328906T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
DK1517921T3 (da) Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
DE60237282D1 (de) Doppelspezifischer ligand und dessen verwendung
EA020464B9 (ru) Отдельные вариабельные домены антител против сывороточного альбумина
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
WO2004058821A3 (fr) Ligand
CY2019029I2 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
DE60138333D1 (de) Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
CY1109536T1 (el) Βελτιωμενες fc πρωτεϊνες συντηξης
DE60332774D1 (de) Verbesserte sso7-polymerase-konjugat-proteine
DK1766093T3 (da) Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
IL172871A (en) Isolated human antibody or antigen-binding section, training linker, single-chain antibody molecule, polypeptide containing them and their use
BR0204484B1 (pt) elemento deslizante.
NO20006704D0 (no) Oppvarmet undersjöisk rörledning
CY1111435T1 (el) Διπλα-ειδικος συνδετηρας και χρηση αυτου
ATE377608T1 (de) Hemoglobin konjugate
MY142617A (en) Dual specific ligands with increased serum half-life
ITRM20010076V0 (it) Linea altachiara.
ES1046444Y (es) Dispositivo de union de las tapas de un album o libro.
ES1046710Y (es) Caja-libro mejorada.
ES1041014Y (es) Album didactico.
ES1056188Y (es) Emisor de ultrasonidos.
ITSV20020059A1 (it) Libro per lettura clinostatica.
IT1314775B1 (it) Procedimento per realizzare e riprodurre blocchi di informazionepersonalizzati e relativo dispositivo.
ES1054552U (es) Dispositivo para la fijacion de elementos tubulares
ITSA20020019A1 (it) Trombone compatto.